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Abstract
It is now well established that the surface of nanoparticles (NPs) in a biological environment is immediately modified by the
adsorption of biomolecules with the formation of a protein corona and it is also accepted that the protein corona, rather
than the original nanoparticle surface, defines a new biological identity. Consequently, a methodology to effectively study
the interaction between nanomaterials and the biological corona encountered within an organism is a key objective in
nanoscience for understanding the impact of the nanoparticle-protein interactions on the biological response in vitro and in
vivo. Here, we outline an integrated methodology to address the different aspects governing the formation and the
function of the protein corona of polystyrene nanoparticles coated with Transferrin by different strategies. Protein-NP
complexes are studied both in situ (in human plasma, full corona FC) and after washing (hard corona, HC) in terms of
structural properties, composition and second-order interactions with protein microarrays. Human protein microarrays are
used to effectively study NP-corona/proteins interactions addressing the growing demand to advance investigations of the
extrinsic function of corona complexes. Our data highlight the importance of this methodology as an analysis to be used in
advance of the application of engineered NPs in biological environments.
Citation: Pitek AS, O’Connell D, Mahon E, Monopoli MP, Baldelli Bombelli F, et al. (2012) Transferrin Coated Nanoparticles: Study of the Bionano Interface in
Human Plasma. PLoS ONE 7(7): e40685. doi:10.1371/journal.pone.0040685
Editor: Vipul Bansal, RMIT University, Australia
Received January 17, 2012; Accepted June 13, 2012; Published July 19, 2012
Copyright:  2012 Pitek et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Authors would like to acknowledge the INSPIRE programme - an Irish Government’s Programme for Research in Third Level Institutions, Cycle 4,
National Development Plan 2007–2013, under which this work was conducted. Additional funding from the EU FP7 Small Collaborative Project NeuroNano
(NMP4-SL-2008-214547) and the Environmental Protection Agency (EPA) project (2008-EH-MS-5) is gratefully acknowledged. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: f.baldelli-bombelli@uea.ac.uk
Introduction
Today nanomaterials are widely used in medicine with an
increasing concern about their possible long-term undesirable
effects on humans. Even with major progress in effective
application of such nanomaterials, their behaviour in vivo remains
poorly characterized. To evaluate the potential impact of
engineered nanomaterials on human health and to improve their
performance, it is essential to study their behaviour in biological
media [1–3].
It is now well established that the surface of nanoparticles (NPs)
in a biological environment is immediately modified by the
adsorption of biomolecules such as proteins, lipids, glycans, etc.
with the formation of the so-called protein corona [4–9]. It is also
accepted that the protein corona, rather than the pristine NP itself,
defines the biological identity of NPs [7,10–14]. The physico-
chemical properties of such particle-protein complexes are
different than those of the formulated particles and the nature of
adsorbed proteins will determine the possible interactions in the
biological environment. Clearly, the understanding of the protein-
nanoparticle interaction represents a crucial step for predicting
NPs biodistribution in vivo with obvious implications for clearance
by macrophage uptake and possible toxicity due to activation of
defence responses, such as clotting or complement [7,15–17].
Consequently, the need of a new common methodology to
effectively study the interaction between nanomaterials and the
biological corona encountered within an organism is a key
objective in nanoscience. In the literature, there are countless
examples of newly engineered nanomaterials aiming either to
target specific body compartments [18–21], or to work as
diagnostic and therapeutic agents [13,22–28]. However, these
nano-objects are often not fully characterized in the relevant
biological environment, where they are normally distinguished by
a new biological interface interacting with the living matter. The
lack of definition of the real biological surface of the nanomaterials
in situ can be an obstacle to clear interpretation of the impact of the
NP-protein interactions on the biological response in vitro and in
vivo.
Here, we outline a methodology to address the different aspects
governing the formation and the function of the protein corona. In
this regard, we functionalize standard polystyrene NPs (bearing
either sulphonated or carboxylated groups) with Transferrin (Tf),
using two different immobilization strategies and we use these
modified NPs to examine the relevant aspects to consider when
nanomaterials are intended for a biological use. In particular, we
coat the surface of polystyrene NPs, namely sulphonated
(PSOSO3H) and carboxylated (PSCOOH), with human holo-
transferrin (Tf) by both physical adsorption and covalent bonding,
and study their stability in human plasma. While PSOSO3H NPs
are only coated by physical adsorption (Tf@PSOSO3H), carbox-
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ylic NPs are coated by both physical adsorption and covalent
bonding (Tf@PSCOOH and Tf-PSCOOH, respectively)
(Figure 1a–b). Holo-Transferrin is an abundant human plasma
glycoprotein (about 79 kDa), which transports iron and binds to
the Tf-receptor (TfR) in the iron-bound form, activating receptor
mediated endocytosis [29,30]. Since tumour cells have a higher
demand for iron they generally overexpress the TfR, thus Tf has
been largely used to functionalize nanomaterials, for its potential
to target cancer cells [18,31–34]. This study has allowed us to
compare Tf-NP bioconjugates for the same core NPs with different
functional groups, highlighting their importance in defining the
NP affinity to the protein rather than the material of the core.
These NPs are characterized in physiological phosphate buffer, to
ensure the formation of monodispersed Tf-NP bioconjugates.
Then, we investigate their properties in 55% human plasma which
allows us to relate any change in the resulting protein-NP
complexes to different surface properties and to define NPs
bionano surface: protein-NP complexes are studied both in situ (in
human plasma, full corona FC) and after washing (hard corona,
HC) in terms of structural properties, composition and second-
order interactions with protein microarrays.
Results
Characterization of Tf-coated Nanoparticles
Tf has been passively adsorbed on carboxylated and sulpho-
nated polystyrene nanoparticles (100 nm) to form monodisperse
stable Tf coated NPs (Tf@PSOSO3H and Tf@PSCOOH).
Sulphonated NPs are relatively hydrophobic so the protein
binding is expected to be stronger than for carboxylic ones. This
is also shown by the estimated amount of Tf adsorbed to NPs
surface, which is ,1.2 times higher for PSOSO3H NPs (see
Table 1). Carboxylated-modified NPs have also been covalently
coupled with Tf resulting in the formation of stable Tf-conjugates.
Details about the procedures used to functionalize these NPs are
reported in the Experimental Section.
These NPs were characterized by Dynamic Light Scattering
(DLS), Z-potential measurements and Differential Centrifugal
Sedimentation (DCS), to ensure the formation of monodispersed,
Figure 1. Strategies of PS NPs functionalization with Tf. Cartoon representation of 100 nm polystyrene NPs modified with sulphonated
groups (PSOSO3H, upper) and carboxylic groups (PSCOOH, down) coated with Tf by either physical adsorption (Tf@PSOSO3H and Tf@PSCOOH) or
covalent coupling (Tf-PSCOOH): A, pristine NPs; B, Tf coated NPs; C, Tf coated NPs after incubation in human plasma. Both Tf@PSOSO3H and Tf-
PSCOOH NPs are stable in human plasma, while Tf on Tf@PSCOOH NPs is easily replaced by environmental proteins.
doi:10.1371/journal.pone.0040685.g001
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and stable bio-coated nano-objects. The increase in the hydrody-
namic diameters without major changes in the PDI together with
the drop in the z-potential upon Tf conjugation for all samples
indicates formation of Tf coated NPs (Table 1). More resolved
DCS measurements reveal more details about the size distribution
of the bio-conjugates with respect to the unfunctionalized NPs: the
particle size distribution resembles that of the pristine NPs for Tf@
PSOSO3H, while for both Tf@PSCOOH and Tf-PSCOOH NPs,
even if the monomer population is always dominant, a tendency to
form multiparticle-protein assemblies (mostly dimer and trimer) is
observed (Figure 2A–C). The formation of dimer and trimer
complexes is more enhanced for covalently coupled Tf-PSCOOH
NPs where possible protein cross-linking can occur with further
particle bridging. From DCS data, knowing the shape and internal
density distribution of the conjugates, it is possible to compute the
thickness of Tf-shell for the monomer Tf-NP conjugates. This can
be done using a simple core-shell two-density model involving the
particle material and the adsorbed protein densities (see Model
S1). Tf shells (dTf) reported in Table 2 are about 4–5 nm for all
samples, which is in good agreement with the formation of a full Tf
coverage. The structural characterization indicates the formation
of stable well-dispersed Tf-coated NPs.
Immunological assay (dot-blots) with monoclonal anti-Tf and
anti-HSA gives a strong recognition of functionalized NPs by anti-
Tf, as expected, and a weaker recognition by anti-HSA, indicating
presence of small amount of albumin in the coating of all samples
(Figure 2D). The binding of Tf@NPs at the specific regions of the
dot-blots has been revealed by detection of NPs fluorescence.
Albumin is also present, in low percentage, in the Tf stock solution
(being the most abundant protein in human plasma) and,
considering its lower concentration during incubation, the
adsorption on the NP surface implies a higher affinity of albumin
to associate to the NPs than Tf. MS analysis on the removed
protein layer for physically coated NPs indicate that the
percentage of albumin is less than 1% and about 1.5% of the
total protein amount for Tf@PSOSO3H and Tf@PSCOOH,
respectively (Table S1 in the SI).
Protein Corona Structure and Composition of Tf-coated
NPs in Human Plasma
We study the behaviour of Tf-coated NPs in situ in 55% human
plasma solution (v/v in PBS). DCS measurements of NP-protein
complexes in situ in 55% plasma (full corona, FC) and once isolated
from plasma (hard corona, HC), show that these complexes can be
physically isolated from the surrounding medium and studied in
detail, without significantly altering their structure and size
distribution (Figure 3A–C). Moreover, the formation of NP-
protein complexes occurs in the first five minutes of incubation
(Figures 3D–F). The evaluation of the thickness of the protein
corona shell shows that Tf pre-coating inhibits the protein corona
formation with respect to the pristine polystyrene NPs [7,35] for all
NPs, but to a different extent (reported in Table 2). Tf@
PSOSO3H FC complexes in situ, although slightly larger, preserve
the same size distribution as in PBS, suggesting minor adsorption/
exchanging with the environmental proteins. In fact, the
corresponding HC complexes isolated from the excess of plasma
show the same size as in PBS indicating that the environmental
proteins are weakly associated to the NPs (see Figure 3A,D). Tf@
PSCOOH FC complexes in situ and isolated from plasma (HC) are
more monodispersed than in PBS, but show the formation of an
extra protein layer on the Tf coating, implying major exchange/
adsorption with the environmental proteins (Figure 3B,E). Finally,
Tf covalent linkage to the NP surface appears to be more effective
in hampering protein adsorption from the environment; in fact
both FC and HC NP-protein complexes do not show major
changes in the size of monomer complexes with respect to those in
PBS (Figure 3C,F).
Figures 4A and 4C illustrate SDS-PAGE of the protein corona
of Tf coated particles in comparison to pristine polystyrene NPs
incubated in 55% plasma at different incubation times (5 min and
1 hr). The results are in very good agreement with the structural
investigation: Tf@PSOSO3H and covalently bound Tf-PSCOOH
NPs do not show major adsorption of environmental proteins
upon incubation in plasma, while the protein corona composition
of Tf@COOH NPs is significantly affected by plasma incubation.
The latter sample shows a major decrease in the intensity of the
80 kDa band (Tf molecular weight) and detection of new bands at
lower Mws. A more quantitative evaluation of the loss of Tf after
incubation in human plasma is achieved by WB (Figures 4B and
4D). Western-blot analysis of the protein corona of Tf coated NPs
incubated in plasma, against polyclonal anti-Tf antibody shows
that Tf exchange with environmental proteins occurs as soon as
the particle comes into contact with the fluid, since no changes are
detected over 1 hour. In particular, Tf desorption qualitatively
evaluated by densitometry analysis of the bands is about 30% and
60% from sulphonated and carboxylated NPs, respectively. The
protein-coating detached from Tf-PSCOOH NPs is not recog-
nised by anti-Tf antibody as expected (Figure 4D). In fact, Tf-
PSCOOH NPs are extensively purified to remove any excess of
unbound Tf after their synthesis (see Figure S1) and SDS-PAGE
after incubation in 55% plasma does not show formation of a
multi-protein corona (Figure 4C).
MS analysis agrees with these results, showing a large decrease
in the detection of Tf upon incubation in plasma for carboxylated
Tf coated NPs and a slight diminution for the sulphonated ones
(Table 3). MS analysis gives more insights on the composition of
the gel band at 80 kDa and indicates histidine-rich glycoprotein
and Fibrinogen/HSA as the most abundant proteins for sulpho-
nated and carboxylated Tf@NPs, respectively. MS analysis of the
moiety of the gel corresponding to 80 kDa for covalently coated
carboxylated NPs highlights the presence of environmental
proteins, but the low values of the peptide hits indicate their low
abundance.
Interactions of Tf-coated NPs at the Bionano Interface
We have shown that the investigated Tf coated polystyrene
NPs are characterized by a different bionano interface in
human plasma and presumably this will affect their interaction
with the living matter in vivo. We further explore the extrinsic
Table 1. DLS analysis of bare and Tf coated polystyrene
nanoparticles in PBS (pH 7.4) at 25uC.
Sample DH [nm]
[a] PDI[b]
z-potential
[mV] Tf [mg/mgNP][c]
PSOSO3H 129.9+/22.2 0.099 235.7 –
Tf@PSOSO3H 146.4+/22.1 0.075 210.4 154+/29
PSCOOH 117.8+/22.2 0.034 238.6 –
Tf@PSCOOH 141.9+/26.3 0.080 214.4 125+/219
PSCOOH-Tf 135.5+/26.7 0.071 212.2 165+/225
[a]z-average hydrodynamic diameter extracted by cumulant analysis of the data.
[b]Polydispersity index from cumulant fitting.
[c]Tf amount for nanoparticle estimated according to the procedure described
in method section.
doi:10.1371/journal.pone.0040685.t001
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physical interactions displayed at the bionano interface formed
in the relevant biological fluid studying the binding of protein
corona complexes with selected human plasma proteins. Figure 5
qualitatively illustrates that Tf coated NPs in PBS interact
differently with the spotted proteins, in particular both Tf@
PSOSO3H (Figure 5A) and Tf-PSCOOH (Figure 5E) NPs do
not show strong interaction with the spotted proteins, giving
only a faint signal for IgM. Upon incubation in plasma Tf@
PSOSO3H (Figure 5B) and Tf-PSCOOH (Figure 5F) HC
complexes do not show major changes in the interaction with
the spotted proteins with respect to in PBS, confirming the
stability of Tf coating. Instead, Tf@PSCOOH NPs (Figure 5C1)
give a more complex interaction pattern, which is remarkably
similar to the one of the original carboxylated NPs (Figure 5C2).
The only difference is that the affinity to Fibrinogen, the
strongest hit for the pristine carboxylated NPs, is significantly
reduced by Tf coating. In plasma, Tf@PSCOOH HC
complexes are again very similar to that of the bare PSCOOH.
Figure 2. Characterization of Tf coated NPs in PBS at room temperature. Differential centrifugal sedimentation (DCS) results for: A, 100 nm
PSOSO3H NPs and Tf@PSOSO3H NPs; B, 100 nm PSCOOH NPs and Tf@PSCOOH NPs and C, 100 nm PSCOOH NPs and Tf-PSCOOH. All size distributions
show a shift towards larger apparent sizes in the presence of Tf coating. D, immuno detection of Tf coated NPs against monoclonal anti-Tf and anti-
HAS.
doi:10.1371/journal.pone.0040685.g002
Table 2. DCS characteristics of Tf precoated NPs; hard corona (HC) and full corona (FC).
Particle
Dapp PBS
[nm] dTrf [nm]
Dapp(HC) 5 min
[nm]
dHC 5 min
[nm]
Dapp(HC)
1 h [nm]
dHC 1 h
[nm]
Dapp(FC)
1 h [nm]
dHC 1 h
[nm]
PSOSO3H 104.5 – agg – agg – agg –
PSCOOH 119.2 – – – 160.8 ,5.5 175.0 ,7.5
Tf@PSOSO3H 138.6 ,4.5 136.9 ,4.0 136.4 ,4.0 143.4 ,5.0
Tf@PSCOOH 151.2 ,4.0 161.9 ,5.5 162.7 ,5.5 172.3 ,7.0
PSCOOH-Tf 155.5 ,4.5 156.0 ,4.5 155.9 ,4.5 155.0 ,4.5
doi:10.1371/journal.pone.0040685.t002
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This behaviour is probably related to the formation of very
comparable protein coronas in plasma for these two particles
(gel reported in Figure 4C). As expected, the ‘‘covalent linkage’’
approach results in a more stable coating whose extrinsic
interactions are not significantly affected by the biological milieu
as shown in Figures 5E–F. Direct Tf covalent conjugation to
PSCOOH NPs decreases the surface energy of the nano-object,
reducing plasma protein adsorption with almost no formation of
the protein corona. Thus, the protein coating, although
decreasing the surface charge and electrostatic repulsion energy,
reduces protein binding on exposure to plasma [36,37].
However, Tf@PSOSO3H NPs do not show significant exchange
Figure 3. DCS measurements of Tf coated NP-corona complexes before and after incubation in plasma. A–C, apparent size comparison
between Tf coated NPs dispersed in PBS, NPs incubated in plasma and isolated by spinning (so called hard corona) and NPs incubated in plasma ‘‘in
situ’’ (so called full corona); D–F, the particle-corona complexes were isolated after either 5 min or 1 hour of incubation in the biological fluid. DCS
experiment for the same NPs in PBS is reported for comparison in all graphs.
doi:10.1371/journal.pone.0040685.g003
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with environmental proteins and extrinsic interactions seem
preserved in the relevant biological milieu. Accordingly,
physically adsorbed bio-coatings can be very stable in situ in a
relevant biological fluid as well, when the interaction between
the functional groups on the NP surface and the biomaterial is
sufficiently strong.
Figure 4. Evaluation of Tf content in the NP coatings by SDS-PAGE and Western Blot. Analysis of the protein coating in PBS and after
incubation in 55% human plasma. A, SDS-PAGE of Tf@PSOSO3H NPs in PBS after 5 min and 1 hour of incubation in human plasma (after washing).
Protein coronas of the pristine PSOSO3H NPs after 5 min and 1 hour incubation are reported as reference; B, western blot analysis of the gel reported
in Figure A against polyclonal anti-Tf and densitometry of the bands; C, SDS-PAGE of Tf@PSCOOH and Tf-PSCOOH NPs in PBS and after 5 min and 1
hour of incubation in human plasma (after washing). Protein coronas of the pristine PSCOOH NPs after 5 min and 1 hour incubation are reported as
reference; D, western analysis of the gel reported in panel C against polyclonal anti-Tf and densitometry of the bands.
doi:10.1371/journal.pone.0040685.g004
Table 3. Mass spectrometry data for human Tf amount on precoated PS nanoparticles before and after incubation in human
plasma.
Sample Peptide Ions [Hits] Norm Peak Area [% area]
Tf@PSOSO3H 143.00 99.12
Tf@PSOSO3H 5 min inc. (55% plasma) 125.00 96.52
PSOSO3H 5 min inc. (55% plasma) 24.00 1.21
Tf@PSCOOH 182.00 97.82
Tf@PSCOOH 5 min inc. (55% plasma) 106.00 58.74
PSCOOH-Tf 33.00 58.51
PSCOOH-Tf 5 min inc. (55% plasma) 7.00 3.22
PSCOOH 5 min inc. (55% plasma) 19.00 1.20
doi:10.1371/journal.pone.0040685.t003
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A better understanding of the resulting interaction pattern
(‘interactome’) of Tf@PSOSO3H protein corona complexes in
human plasma is obtained studying their functional interaction
with 9,483 full-length eukaryotically expressed proteins on high
content human protein microarrays (Table S2 in the SI). In
biological systems, not all of these proteins will be accessible to
plasma-borne particles, but they usefully represent the in situ
biological identity of the particles if compared to their ‘inter-
actome’ in PBS. In fact, this approach could be also used to test
the specific biological interactions displayed by Tf coated layers
with respect to the free protein, i.e. the ability of Tf to exploit its
biological function when adsorbed or linked to the NP surface. It is
important to note that neither TfR nor other known functional
binders of Tf (STRING algorithm, http://string-db.org/) (see
Table S3) are present in these commercially available high content
human protein microarrays. Indeed, fluorescently labelled Tf does
not show any specific interactions with the arrayed proteins (data
not shown).
The main purpose of our present study is to evaluate how
physical interactions between Tf@PSOSO3H NPs and arrayed
human proteins change in the presence of environmental proteins,
when different competing processes are simultaneously taking
place: protein corona complexes interacting with arrayed proteins,
free plasma proteins interacting with protein corona complexes
and free proteins interacting with arrayed proteins [11]. However,
in the future custom arrays could be used to test the binding of
functionalized NPs to selected targets in situ, in the biological fluid.
We investigate four different samples on the protein micro-
arrays: pristine PSOSO3H and Tf@PSOSO3H NPs both in PBS
and in 55% human plasma in the same experimental conditions. It
is noteworthy that uncoated NPs form large protein-NP aggregates
in plasma as reported in Table 2 and in previous studies [7], thus
the corona complexes are very different both in terms of structure
and composition from those formed by Tf@PSOSO3H. We find
that sulphonated NPs, unsurprisingly (due to their high surface
energy), in the absence of plasma bind to most proteins on the
array (Figure 6A) where 5500 positive spots can be detected, and
the majority of these interactions are similar to each other
(Figures 7A–B) indicating that non-specific interactions between
particle surface and typical proteins are similar across the array.
The strength of all these bare surface-protein interactions strongly
decreases over incubation in human plasma, when protein-NP
Figure 5. Human plasma protein dot-blots of Tf coated NPs and their HC in 55% plasma. 1 mM (a) and 0.1 mM (b) solutions of human
plasma proteins were spotted on the membrane to interact with functionalized NPs. Protein list: 1) HSA 2) Fibrinogen 3) Apo-E 4) Apo-AI 5)
Plasminogen 6) Apo-B 7) Apo-AII 8) IgM 9) IgG and 10) Apo-C1.
doi:10.1371/journal.pone.0040685.g005
Study of the Bionano Interface in Human Plasma
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e40685
complexes are formed (see Figure 6B). In this case, the total
number of positive spots lowers to about 100 (see Figure 7A,C),
but most of the interactions are comparable in term of strength (on
the base of fluorescent intensity), presumably revealing a typical
energy scale of non-specific interactions between hard corona and
target array proteins. The most intense positive spots are from
proteins, which cannot be related to any known specific
interaction with the proteins in the corona of the NPs.
Tf coating on sulphonated NPs, as expected, strongly decreases
the strength of interactions with the arrayed proteins both in terms
of intensity and number of positive spots, but the general trend of
the binding profile (Figure 7B), which resembles that of pristine
sulphonated NPs, reflects a non-specific nature of most interac-
tions. A more detailed analysis reveals that most of the proteins in
the array bound by Tf@PSOSO3H NPs are positive for the
pristine sulphonated NPs as well, with the only exception of
dynamin 2, the second highest positive spot (Tables S4a and S4c in
the SI), which does not present any known relation to Tf. Finally,
the ‘‘interactome’’ of Tf@PSOSO3H NPs in human plasma,
where there is no evidence of the formation of a thick robustly
bound protein corona, is strongly decreased in number and
strength of the interactions (Figure 6D and 6C), indicating that the
competition with free environmental proteins is significantly
affecting the binding pattern to the arrayed proteins. It is also
interesting that among the 14 interactions only five are shared with
those displayed in PBS (see Table 4), which appear more intense in
absence of plasma. The 10 emergent new interactions in the
biological fluid are not listed as known binders to either Tf or to
other plasma proteins.
Discussion
The generally accepted view in nanomaterial research for
biological applications is that the biologically relevant unit is not
the pristine particle, but a nano-composite of specified size,
shape, and selective protein corona structure. It has been
extensively elucidated how NP size and functional groups can
significantly shape the protein corona of the same bulk material
nanoparticles [12,16,38,39] and here we address the effect of a
protein coating on the formation of the corona in a biological
fluid. Our results clearly show how functional groups determine
the stability of physically adsorbed protein-NP conjugates much
more than the bulk material. In fact, if NP incubation with Tf
succeeds in the formation of stable, monodisperse monomer Tf
coated conjugates, for both sulphonated and carboxylated
polystyrene NPs (see Figure 2 and Table 1), DCS results on
FC and HC protein complexes clearly indicate that physical Tf
pre-coating inhibits the formation of a robust protein corona in
the biological environment for sulphonated NPs (see Table 2
and Figure 3), but not for carboxylated ones. These structural
findings are strongly supported by the biological investigation
(SDS-PAGE, WB and MS analysis) reflecting very little
exchange of Tf with the environmental proteins for Tf@
PSOSO3H NPs. Tf@PSCOOH NPs, instead, exhibit a
rearrangement at the bionano interface with a big loss of Tf
and consequent formation of a multi-protein corona after
instantaneous contact with environmental proteins. The com-
position of this protein corona, although Tf-enriched, resembles
the protein corona of pristine carboxylated NPs. As expected,
Tf covalent linkage to the surface of carboxylated NPs provides
a stable coating with the formation of monomer bio-conjugates
whose structure and composition is almost invariant on
Figure 6. Tf@PSOSO3H and PSOSO3H NPs incubated on protein arrays. Images of complete protein microarrays incubated with: A, 40 mg/ml
PSOSO3H NPs in PBS (and sub-array 9); B, 40 mg/ml PSOSO3H in 10% human plasma (and miniature of sub-array 9); C, 40 mg/ml Tf@PSOSO3H NPs in
PBS (and sub- array 26); D, 40 mg/ml Tf@PSOSO3H NPs in 10% human plasma (and miniature of sub-array 26).
doi:10.1371/journal.pone.0040685.g006
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Figure 7. Human protein arrays positive hits comparison. A, graph of total positive hits for bare and functionalized NPs in PBS and 10%
human plasma solution; B, fluorescence intensity comparison for positive hits, between bare PSOSO3H NPs and Tf@PSOSO3H in PBS; C, fluorescence
intensity comparison for positive hits, between PSOSO3H NPs and Tf@PSOSO3H in human plasma.
doi:10.1371/journal.pone.0040685.g007
Table 4. The fluorescence intensity for positive interaction hits for Tf@PSOSO3H in 10%plasma and PBS.
No Protein name 10% plasma PBS
1 Homo sapiens hypothetical protein DKFZp434E2220 (DKFZp434E2220), mRNA 72.5 365.5
2 Homo sapiens outer dense fiber of sperm tails 2, mRNA (cDNA clone MGC:9034 IMAGE:3874501), complete cds 65 –
3 Homo sapiens calcium binding and coiled-coil domain 1 (CALCOCO1), mRNA 29 –
4 Homo sapiens complexin 1 (CPLX1), mRNA 28.5 37.5
5 Homo sapiens centaurin, delta 2 (CENTD2), transcript variant 1, mRNA 18 38.5
6 Homo sapiens TruB pseudouridine (psi) synthase homolog 1 (E. coli) (TRUB1), mRNA 15 104
7 Homo sapiens mitochondrial ribosomal protein S23 (MRPS23), nuclear gene encoding mitochondrial protein, mRNA 11.5 –
8 Homo sapiens mitogen-activated protein kinase 9 (MAPK9), transcript variant JNK2-a2, mRNA 8.5 –
9 Removed from database 7 –
10 Homo sapiens protein kinase, AMP-activated, gamma 2 non-catalytic subunit (PRKAG2), mRNA 6 117
11 Homo sapiens mRNA similar to LOC166173 (cDNA clone IMAGE:5203730) 6 –
12 Homo sapiens paraoxonase 3, mRNA (cDNA clone MGC:88384 IMAGE:4710338), complete cds 6 –
13 Homo sapiens lactate dehydrogenase A (LDHA), mRNA 6 –
14 Homo sapiens lipopolysaccharide-induced TNF factor (LITAF), mRNA 4 –
doi:10.1371/journal.pone.0040685.t004
Study of the Bionano Interface in Human Plasma
PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e40685
exposure to plasma (Figure 4C). This does not guarantee the
preservation of the native conformation of the grafted protein
(random coupling between amine groups of the protein with
carboxylic groups on the NP’s surface) and of its biological
function. An additional study on how the covalent coupling
strategy used to modify nano-scaled surfaces with protein
(grafting density, coupling reaction, presence of linker, etc.)
affects their behaviour in a relevant biological fluid and their
specific binding to the biological target is currently in progress
in our laboratory.
In order to elucidate the extrinsic interactions of these
nanoparticles in situ, we model the interaction of proteins resident
in the corona of the nanocomposite on high content protein
microarrays. First, we use human plasma protein dot-blots
(Figure 5), as a simple method to probe the interaction of the
new bionano interfaces with the environmental proteins with
respect to the pristine NPs. For example, the evidence that Tf@
PSCOOH and bare PSCOOH HC complexes give similar
binding pattern with human plasma spotted proteins (Figure 5D1
and 4D2), suggest that preserved Tf (after exposure to plasma) is
strongly associated to the NP surface and does not seem to affect
the physical interactions displayed by these nano-composites in situ.
This result shows how such a simple assay as a dot-blot can give
important information to better outline the local structure of the
protein corona. This result also indicates that the preserved Tf on
the NP surface will very likely be unable to interact with the
desired bio-target (TfR) in vivo. For this reason the more
sophisticated experiments with microarrays were only made with
the Tf@PSOSO3H NPs.
The biological environment is extremely complex and it is
difficult to reproduce it in vitro, thus we propose the use of high
content human protein microarrays as a new approach to
dissect the ‘‘interactome’’ of these NPs in situ. General outcomes
from these experiments are the following, although the
repertoire of the proteins spotted on arrays is not complete.
Lower surface energy Tf coated NPs, as expected, show lower
tendency to bind to the arrayed proteins than bare sulphonated
NPs, and the binding profile does not reflect any emergent
specific interaction except to one protein, dynamin 2, with
respect to uncoated sulphonated NPs in PBS. The possibility of
a new specific interaction between adsorbed Tf and dynamin,
due to the possible exposition of new binding sites for Tf upon
adsorption on the NP surface is unlikely, as this interaction is
not further detected when the NPs are incubated with the
microarray in human plasma. The significant decrease in
number and strength of positive spots for pristine sulphonated
NPs in human plasma is also expected, as environmental
proteins compete in the binding and protein-NP complexes will
have a lower affinity to the arrayed proteins (lower surface
energy). Moreover, even if specific interactions between protein
resident in the corona and arrayed proteins are not detected,
one should be aware of potential exposure of new binding sites
(not necessarily specific) giving new unknown interactions. In
this case, any of the emerging proteins that interact with the
protein corona NPs is relevant to their interaction with the
living matter. However, the most surprising outcome is the
abrupt change in the binding pattern of Tf@PSOSO3H NPs to
the arrayed proteins in plasma with only 14 significant hits. As
hard corona complexes seem to preserve the original structure
and composition of the original Tf coated NPs, this change
cannot be simply related to the formation of a hard corona
layer, unless we involve a contribution of the soft corona, i.e.
the loosely bound proteins in fast exchange with the
environment. In fact, we believe that this result indirectly
reflects a very significant role of the competitive binding
displayed by free environmental proteins in the interaction
between protein corona NPs and living matter (in this case
represented by the arrayed proteins). Presumably, many binding
sites are now engaged and not available to interact with Tf
coated NPs, which are less prone to give physical non-specific
interactions than multi-protein corona complexes as in the case
of the pristine sulphonated NP-corona complexes (Figure 6B,D
and Figure 7A). This can be explained by the presence of more
‘‘binding sites’’ on the multi-protein corona complexes, due to
their richer protein composition. Moreover, none of the 14
positive spots are among the brightest spots in PBS, suggesting
that those interactions (in PBS) are not specific and easily
switched off by stronger binders present in the medium. Only
five of these proteins are also bound by Tf@PSOSO3H in PBS
(not the top five) indicating that the competitive binding from
free medium proteins can also induce a change in the
interaction profile with certain proteins.
Here, we have functionalized different polystyrene NPs
(carboxylated and sulphonated) with Transferrin by both
physical adsorption and covalent bonding, as a relevant example
to address the important aspects governing the behaviour of
bio-coated NPs in situ in a biological fluid. We present an
integrated methodology where we show the importance to
combine physico-chemical, biological and proteomic techniques
for extensive characterization of the properties and the
interactions of these NPs in situ. We show that the surface
chemistry of the NPs has the major impact on the strength of
the interaction with Tf itself as well as on the further stability of
the adsorbed coating in human plasma: both structural (DCS)
and composition analysis (SDS-PAGE, WB and MS) of the
protein corona indicate that Tf@PSOSO3H and Tf-PSCOOH
NPs are stable and do not form strong protein-NP complexes.
For Tf@PSCOOH NPs, instead, the bionano interface is
subjected to rearrangement upon incubation in human plasma
with remarkable similarities to that of the carboxylated original
NPs, as confirmed by the same binding affinity to the spotted
plasma proteins. Finally, we study the interaction of selected
NPs with eukaryotic protein arrays in PBS and in human
plasma. The number and intensity of the positive spots for Tf
coated sulphonated NPs decrease significantly with respect to
those for the protein-corona PSOSO3H NPs, showing that the
absence of a multi-protein corona has a big impact on the
extrinsic interactions of the NPs in situ. These results are
encouraging as they show that, when the Tf coating is strong
and stable in the biological fluid (with no formation of a rich
protein corona), the affinity to bind arrayed proteins signifi-
cantly decreases. Presumably, Tf coated NPs will have a chance
to compete with environmental proteins in binding the arrayed
targets only when a specific interaction is involved, while
uncoated polystyrene NPs decorated by a multi-protein corona
in plasma show a higher tendency to bind the arrayed proteins.
The methodology outlined here could be of some importance in
future, for applications whenever engineered NPs are meant to
be used in a biological environment to either find out new
ligands, due to the exposition of unknown epitopes upon protein
absorption on the NP surface, or to test the specific binding to
a bio-target. We also stress some limitations of this technology
at present, for example the limited repertoire of proteins on the
commercially available arrays reducing the number of specific
targets. We envisage that the next important step in the use of
this technology for studying NP-biomolecule interactions in a
biological relevant fluid is to make custom arrays where specific
binders and ubiquitous proteins are simultaneously present.
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Materials and Methods
Materials
Holo-Transferrin Human (cat. no. T4132), HSA (cat. No.
A9511), IgG (cat. no. I2511), PBS tablets (cat. no. 3671), MES
(cat. no. M3671), EDAC (cat. no. E6383) and glycine (cat. no.
G7126) were all purchased from Sigma-Aldrich. Micro BCA
Protein Assay Kit and Pierce ECL Western Blotting Substrate (cat.
no. 32209) were purchased from Thermo Scientific. Mouse
monoclonal anti-Tf antibody (ab769), rabbit polyclonal anti-Tf
antibody (ab66952), mouse monoclonal anti-HSA antibody
(ab10241) and goat secondary anti-rabbit antibody (ab6721) were
purchased from ABCAM. ApoA-I (cat. no.178452), ApoC-I
(cat.no. 178459), ApoA-II (cat.no. 178455), Fibrinogen
(cat.no. 341576), IgM (cat.no. 401799), ApoE (cat.no. 178468),
ApoB (cat.no. 178456) were all purchased from CALBIOCHEM.
Transferrin – alexa fluorophore conjugates (T13342 and T35352)
were purchased from Invitrogen. The 300 kDa cellulose ester
dialysis tubing (cat. no. 131450) was purchased from Spectrum-
Labs. Blue Loading Buffer for SDS-PAGE was ordered from New
England Bio-Labs (cat. no. B7703S).
Nanoparticles
Fluorescent Polystyrene latex beads, both carboxyl-modified
PSCOOH (100 nm) and sulphonated-modified PSOSO3H
(100 nm), were purchased from Invitrogen by Life Technologies.
All nanoparticles were characterized by measuring their size and
z-potential in physiological buffer before use.
Human Plasma
Blood was withdrawn from 10–15 different volunteers and
collected into 10 ml K2EDTA coated tubes (BD Bioscience).
Plasma was prepared following the HUPO BBB SOP guidelines
[40]. Briefly, immediately after blood collection, each tube was
inverted ten times to ensure mixing of blood with the EDTA, and
subsequently centrifuged for ten minutes at 1300 g at 4uC. Equal
volumes of plasma from each donor were collected into a
secondary 50 ml falcon tube and then centrifuged at 2400 g for
15 minutes at 4uC. Supernatant was collected (leaving approxi-
mately 10% of the volume in the secondary tube) and it was then
aliquoted into 1 ml cryovials and stored at 280uC until use. The
whole procedure did not take more than three hours. Following
this procedure the plasma protein concentration is estimated to be
,80 g/L. When plasma was used for experiments, it was allowed
to thaw at room temperature and centrifuged for 3 min at
16.2 kRCF. Thawed plasma was never re-frozen or re-thawed. All
data presented are obtained using plasma from one donation
session. The blood donation procedure was approved by the
Human Research Ethics committee at University College Dublin.
Preparation of Physically Adsorbed Tf Nanoparticles
(Tf@PSCOOH, Tf@PSOSO3H)
Physically adsorbed Tf@NPs were prepared by incubating bare
polystyrene carboxylic-modified and sulphonate-modified 100 nm
NPs in Tf solution in 50 mM MES (2-(N-morpholino)ethanesul-
fonic acid) buffer at pH=5.9 for two hours at room temperature
with further extensive dialysis against 10 mM PBS buffer at
pH=7.4. Tf concentration was optimized preparing a series of
samples with constant NP concentration (2.2 mg/ml) and multiple
Tf concentrations varying from 0.56 mg/ml to 4.45 mg/ml (see
Figure S2). The amount of adsorbed Tf was quantified with use of
protein assay (Pierce Micro BCA Protein Assay Kit) after dialysis
against PBS buffer. The optimal protein concentration for the
adsorption, guarantying full surface coverage was found to be
2.2 mg/ml.
Preparation of Covalently Bound Tf Nanoparticles (Tf-
PSCOOH)
5 mg of Tf was dissolved in MES 50 mM pH=6 at a
concentration of 2 mg/ml. PSCOOH NPs were dispersed in the
same buffer at a concentration of 2 mg/ml. Equal volumes of each
were mixed by adding particle solution drop-wise to the protein
solution with intermittent shaking. The clear mixture was then left
to mix in a lab incubator for 10 minutes shaking at 500 rpm, after
which 5 mg of EDAC dissolved in 20 ml buffer was added. The
mixture was shaken for a further 2 hours before 10 mg of glycine
was added to quench the reaction. The dispersion was then
dialyzed against 10 mM phosphate buffer pH 7.4 (1624 hrs) in
300 kDa cut-off membrane followed by dialysis against PBS
(3624 hrs).
Sample Preparation
Hard protein coronas on both bare and Tf pre-coated NPs were
prepared by incubating the NPs at concentration of 0.4 mg/ml in
55% human plasma solution (total protein content 34–47 mg/ml)
at room temperature for either 5 minutes or 1 hour. After the
incubation, samples were spun down and washed three times with
0.5 ml PBS. The three washing steps allowed for removal of
proteins loosely bound to NPs surface (so-called soft corona) with
recovering of the so-called hard corona composed of the most
affine proteins. The final pellet was re-suspended in varying
volumes of PBS depending on the experiment. NP samples in situ
for DCS experiments were prepared in the same conditions than
those specified above for hard corona (without spinning down and
washing) and diluted to concentration 0.1 mg/ml with PBS
directly prior injection to DCS gradient.
DLS and Z-potential
DLS measurements at the scattering angle h=173 and Z-
potential determination were performed using a Malvern Zetasizer
3000HSa. Each measurement was an average of twelve repetitions
of ten seconds each and repeated five times. Data analysis has been
performed according to standard procedures, and interpreted
through a cumulant expansion of the field autocorrelation function
to the second order.
Differential Centrifugal Sedimentation (DCS)
Differential centrifugal sedimentation experiments were per-
formed with a CPS Disc Centrifuge DC24000. The CPS Disc
Centrifuge is a particle size analyser for measuring particles in the
range of 0.01 mm to 40 mm. The analyser measures particle size
distributions using centrifugal sedimentation within an optically
clear spinning disc filled with fluid. Sedimentation is stabilized by a
density gradient within the fluid, and accuracy of the measured
sizes is insured through the use of a known size calibration
standard run immediately before each measurement. The use of a
biological sample with a large amount of proteins requires a new
sucrose gradient to be prepared for each measurement. The
concentration of the particles at each size is determined by
continuously measuring the turbidity of the fluid near the outside
edge of the rotating disc. The turbidity measurements are
converted to a weight distribution by Mie theory light scattering
calculations. The choice of the experimental parameters, namely
the fluid gradient, the speed of rotation, etc. is based on the type of
material being analyzed and the range of sizes being measured.
The primary information from the analytical disk centrifuge is the
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time taken for the particles to travel from the centre of the disk
through a defined viscous sucrose gradient to a detector placed at
the outer rim of the disk under a strong centrifugal force. For
materials with homogenous density and simple shape (for example
spherical particles) one can directly relate this time to a particle
size. Where objects are inhomogeneous, or irregular in shape, the
different arrival times still allows one to distinguish between them.
In the simplest approximation one still approximates them to an
equivalent uniform sphere, and this is the meaning of the size cited
on the x-axis of all figures presented and hence it should be
considered as an ‘apparent’ size. Moreover, for the sake of clarity
in the comparison of different samples, we chose to show data as
relative weight particle size distribution. The tallest peak (highest
weight value) in the distribution is called the ‘base’ peak (has a
value of 100%) and all other particle size (multimer) peaks are then
normalized against this base peak to give a relative weight
distribution. It is important to emphasize that the conversion from
absorption raw data to molecular weight data is correct as long as
the optical parameters and the density for particles and fluid are
correct and the particles are spherical.
1D-SDS-PAGE and WB
Tf@NPs and their hard corona complexes were separated and
denatured by boiling for 5 minutes in blue loading buffer
(62.5 mM Tris-HCl (pH 6.8 @ 25uC), 2% (w/v) SDS, 10%
glycerol, 0.01% (w/v) bromophenol blue, 40 mM DTT). So
prepared samples, containing denatured corona proteins coated
with SDS surfactant (which gives them negative net charge) were
separated by size in the moiety of porous 10% polyacrylamide gel
(1D SDS-PAGE), in electric field using a Mini-PROTEAN Tetra
electrophoresis system from Bio-Rad. The electrophoresis was run
under constant voltage of 130 V for about 45 minutes. All the gels
were run in duplicates – one subjected to WB and the second
stained with commassie blue (50% methanol, 10% acetic acid,
2.5% (w/v) brilliant blue) for 3 hours and de-stained overnight in
50% methanol, and 10% acetic acid.
For the Western Blots the protein coronas separated by SDS-
PAGE were transferred from the gel to PVDF membranes using
Mini-PROTEAN Tetra Trans-Blot Module under a constant
voltage of 100 V for 1 hour. The membranes were then incubated
at RT for 1 h in ‘‘blocking solution’’ of 5% skimmed milk in TBS-
TWEEN (150 mM NaCl, 10 mM Tris HCl, 0.1% Tween,
pH7.5). Afterwards, blots were incubated (4uC, overnight) with
0.4 mg/ml rabbit polyclonal antibody against human transferrin in
‘‘blocking solution’’ and subsequently washed in 3615 minutes in
TBS-TWEEN. After washing membranes were incubated with
0.1 mg/ml of horseradish-coupled goat anti-rabbit antibody in
‘‘blocking solution’’ for 1 hour in RT and washed 3615 minutes in
TBS-TWEEN and 165 minutes in Millipore water. Specific
antibody binding was visualized using Pierce Enhanced Chemi-
Luminescence (ECL) Western Blotting Substrate and X-ray
photographic films.
Both Commassie stained gels and Western Blots were scanned
using Bio-Rad GS-800 Calibrated Densitometer and densitometry
was performed using TotalLab Quant software.
Mass Spectrometry
After the SDS-PAGE separation of the protein-NP complexes,
gel lanes were excised and the bands taken from each lane prior to
trypsin digestion and mass spectrometry. All samples were run on
a Thermo Scientific LTQ ORBITRAP XL mass spectrometer
connected to an Exigent NANO LC.1DPLUS chromatography
system incorporating an auto-sampler. Tryptic peptides were
resuspended in 0.1% formic acid. Each sample was loaded onto a
Biobasic C18 PicofritTM column (100 mm length, 75 mm ID) and
was separated by an increasing acetonitrile gradient, using a
120 min reverse phase gradient (0–40% acetonitrile for 90 min) at
a flow rate of 30 nL min21. The mass spectrometer was operated
in positive ion mode with a capillary temperature of 200uC, a
capillary voltage of 46 V, a tube lens voltage of 140 V and with a
potential of 1800 V applied to the frit. All data was acquired with
the mass spectrometer operating in automatic data dependent
switching mode. A high resolution MS scan was performed using
the Orbitrap to select the 5 most intense ions prior to MS/MS
analysis using the Ion trap. The raw mass spectral data was
analysed using Bioworks Browser 3.3.1 SP1, a proteomics analysis
platform. All MS/MS spectra were sequence database searched
using the algorithm TurboSEQUEST. The MS/MS spectra were
searched against a IPI 3.5 database. The following search
parameters were used: precursor-ion mass tolerance of 2 Da,
fragment ion tolerance of 1.0 Da with methionine oxidation and
cysteine carboxyamidomethylation specified as differential modi-
fications and a maximum of 2 missed cleavage sites allowed.
Protein Microarrays
The Protoarray microarray slide (Invitrogen) was blocked by
incubation in 1% skim milk powder dissolved in PBS with 1 mM
DTT, 0.1% Tween 20 and 50% glycerol pH 7.5 for one hour and
then washed once in PBS pH 7.5. The 100 nm PSOSO3H and
Tf@PSOSO3H NPs were diluted to a final concentration of
40 mg/ml either in PBS or in a buffer containing human plasma
diluted to a final concentration of 10%. Before imaging the slide
was washed once in PBS and rinsed in deionized water.
Microarray slides were scanned in a Genepix 4000B scanner
(Axon Instruments). The PMT gain settings were maintained at
500 and 250 for the 635 nm and 532 nm lasers respectively. The
focus position was 10 mm. The microarrays used were all from the
same lot and the gal file specific to the lot of microarrays was
downloaded from the Invitrogen webpage. The gpr results files
from the array scans were analyzed with the Prospector software
(Invitrogen) using the small molecule fluorescence settings.
Dot-blots
The dot-blots were prepared by spotting 1 mL of either the 10
selected plasma proteins (1 mM and 0.1 mM solutions in 10 mM
PBS) or selected antibodies (100 mg/ml, 20 mg/ml and 10 mg/ml
solutions in 10 mM PBS) on PVDF membrane, previously
activated in methanol and equilibrated in 10 mM PBS. So
prepared blots were blocked in 5% skimmed milk solution in
10 mM PBS for 1 hour in RT, washed three times for 5 min in
10 mM PBS and incubated in 40 mg/ml NPs solution in PBS for 1
hour at RT. After subsequent 365 min washes in PBS, blots were
dried and imaged for fluorescence using the ‘‘TYPHOON 9200’’
imager. NPs fluorescence indicate the regions of the blot, to which
NPs attached as a result of positive interactions between Tf on NP
surface and protein spotted on the dot-blot. Scanner settings:
excitation wavelength 532 nm, emission wavelength 555 nm,
normal sensitivity, PMT 350 V.
Supporting Information
Figure S1 Covalently bound Tf-PSCOOH NPs under-
gone to dialysis for different times. The NPs have been
treated to strip the Tf layer off from the surface and the recovered
protein solution analysed by SDS-PAGE (silver staining). The
physical adsorbed Tf component seems to be removed after 98
hours of dialysis.
(TIFF)
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Figure S2 The transferrin adsorption curves for the
PSCOOH and PSOSO3H NPs. The increase of the Tf solution
concentration while adsorption on NPs leads to increase of the
amount of Tf shell on NPs.
(TIFF)
Table S1 Mass Spectrometry data for Tf coated nano-
particles before and after plasma incubation (55%).
(DOCX)
Table S2 ProtoArrayH v4.1 content and distribution by
class.
(DOCX)
Table S3 The main Tf binders according to STRING
algorithm.
(DOCX)
Table S4 Complete list of positive protein microarray
interaction hits for Tf@PSOSO3H NPs in PBS (a),
Tf@PSOSO3H NPs in 10% plasma (b), PSOSO3H NPs
in PBS (c) and PSOSO3H NPs in 10% plasma (d).
(XLSX)
Model S1 Core-shell model analysis for DCS data.
(DOCX)
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